Novo Holdings returned for a $110m series C1 round for Praxis Precision Medicines, four months after the gene therapy developer emerged from stealth with $100m in funding.
Praxis Precision Medicines, a US-based gene therapy developer focusing central nervous system disorders, collected $110m in series C1 funding yesterday from investors including pharmaceutical firm Novo Holdings.
Eventide Asset Management led the round, which also included Vida Ventures, Blackstone Life Sciences, OCV Partners, Avoro Capital Advisors, Surveyor Capital, Point72, Cormorant Asset Management, Qatar Investment Authority, Irving Investors, Adage Capital Management, Verition Fund Management and Ample Plus Fund.
Founded in 2015, Praxis Precision Medicines is developing gene therapies for conditions linked…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
